Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Kura amended employment agreements for CEO Troy Wilson, CCO Brian Powl, and COO Kathleen Ford, primarily revising severance provisions.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Kura amended employment agreements for CEO Troy Wilson, CCO Brian Powl, and COO Kathleen Ford, primarily revising severance provisions
- Standard termination severance: 12 months’ base salary plus up to 12 months’ COBRA and extended option exercise periods
- Change-in-control severance window: 59 days before through 18 months after transaction closing
- CEO change-in-control protection: 24 months’ salary, 200% target bonus, 24 months’ COBRA, and full equity vesting acceleration
- CCO and COO change-in-control protection: 18 months’ salary, 150% target bonus, 18 months’ COBRA, and full equity vesting acceleration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.